Literature DB >> 30250888

An unexpected tumor suppressor role for VAV1a.

Xosé R Bustelo1,2,3, L Francisco Lorenzo-Martín1,2,3, Myriam Cuadrado1,2,3, Isabel Fernández-Pisonero1,2, Javier Robles-Valero1,2,3.   

Abstract

RHO GDP/GTP exchange factors, including VAV1, are considered key protumorigenic factors. Against this paradigm, we have found that VAV1 plays tumor suppressor roles by buffering NOTCH1 signals in thymocytes. The silencing of this pathway contributes to the pathogenesis of T cell acute lymphoblastic leukemia of the early cortical, TLX+ subtype.

Entities:  

Keywords:  Cbl-b; Notch1; Rho GEFs; Rho GTPases; TLX; Vav1; lymphoma

Year:  2018        PMID： 30250888      PMCID： PMC6149884          DOI： 10.1080/23723556.2018.1432257

Source DB:  PubMed          Journal:  Mol Cell Oncol        ISSN： 2372-3556


  10 in total

Review 1.  The molecular basis of T cell acute lymphoblastic leukemia.

Authors:  Pieter Van Vlierberghe; Adolfo Ferrando
Journal:  J Clin Invest       Date:  2012-10-01       Impact factor: 14.808

Review 2.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

Authors:  Dominico Vigil; Jacqueline Cherfils; Kent L Rossman; Channing J Der
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

3.  The rho exchange factors vav2 and vav3 control a lung metastasis-specific transcriptional program in breast cancer cells.

Authors:  Carmen Citterio; Mauricio Menacho-Márquez; Ramón García-Escudero; Romain M Larive; Olga Barreiro; Francisco Sánchez-Madrid; Jesús M Paramio; Xosé R Bustelo
Journal:  Sci Signal       Date:  2012-10-02       Impact factor: 8.192

4.  Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas.

Authors:  Francesco Abate; Ana C da Silva-Almeida; Sakellarios Zairis; Javier Robles-Valero; Lucile Couronne; Hossein Khiabanian; S Aidan Quinn; Mi-Yeon Kim; Maria Antonella Laginestra; Christine Kim; Danilo Fiore; Govind Bhagat; Miguel Angel Piris; Elias Campo; Izidore S Lossos; Olivier A Bernard; Giorgio Inghirami; Stefano Pileri; Xosé R Bustelo; Raul Rabadan; Adolfo A Ferrando; Teresa Palomero
Journal:  Proc Natl Acad Sci U S A       Date:  2017-01-06       Impact factor: 11.205

5.  Melanoma genome sequencing reveals frequent PREX2 mutations.

Authors:  Michael F Berger; Eran Hodis; Timothy P Heffernan; Yonathan Lissanu Deribe; Michael S Lawrence; Alexei Protopopov; Elena Ivanova; Ian R Watson; Elizabeth Nickerson; Papia Ghosh; Hailei Zhang; Rhamy Zeid; Xiaojia Ren; Kristian Cibulskis; Andrey Y Sivachenko; Nikhil Wagle; Antje Sucker; Carrie Sougnez; Robert Onofrio; Lauren Ambrogio; Daniel Auclair; Timothy Fennell; Scott L Carter; Yotam Drier; Petar Stojanov; Meredith A Singer; Douglas Voet; Rui Jing; Gordon Saksena; Jordi Barretina; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Melissa Parkin; Wendy Winckler; Scott Mahan; Kristin Ardlie; Jennifer Baldwin; Jennifer Wargo; Dirk Schadendorf; Matthew Meyerson; Stacey B Gabriel; Todd R Golub; Stephan N Wagner; Eric S Lander; Gad Getz; Lynda Chin; Levi A Garraway
Journal:  Nature       Date:  2012-05-09       Impact factor: 49.962

6.  Pan-cancer analysis of homozygous deletions in primary tumours uncovers rare tumour suppressors.

Authors:  Jiqiu Cheng; Jonas Demeulemeester; David C Wedge; Hans Kristian M Vollan; Jason J Pitt; Hege G Russnes; Bina P Pandey; Gro Nilsen; Silje Nord; Graham R Bignell; Kevin P White; Anne-Lise Børresen-Dale; Peter J Campbell; Vessela N Kristensen; Michael R Stratton; Ole Christian Lingjærde; Yves Moreau; Peter Van Loo
Journal:  Nat Commun       Date:  2017-10-31       Impact factor: 14.919

7.  TIAM1 Antagonizes TAZ/YAP Both in the Destruction Complex in the Cytoplasm and in the Nucleus to Inhibit Invasion of Intestinal Epithelial Cells.

Authors:  Zoi Diamantopoulou; Gavin White; Muhammad Z H Fadlullah; Marcel Dreger; Karen Pickering; Joe Maltas; Garry Ashton; Ruth MacLeod; George S Baillie; Valerie Kouskoff; Georges Lacaud; Graeme I Murray; Owen J Sansom; Adam F L Hurlstone; Angeliki Malliri
Journal:  Cancer Cell       Date:  2017-04-13       Impact factor: 31.743

8.  The Rho exchange factors Vav2 and Vav3 favor skin tumor initiation and promotion by engaging extracellular signaling loops.

Authors:  Mauricio Menacho-Márquez; Ramón García-Escudero; Virginia Ojeda; Antonio Abad; Pilar Delgado; Clotilde Costa; Sergio Ruiz; Balbino Alarcón; Jesús M Paramio; Xosé R Bustelo
Journal:  PLoS Biol       Date:  2013-07-23       Impact factor: 8.029

Review 9.  Vav family exchange factors: an integrated regulatory and functional view.

Authors:  Xosé R Bustelo
Journal:  Small GTPases       Date:  2014

10.  A Paradoxical Tumor-Suppressor Role for the Rac1 Exchange Factor Vav1 in T Cell Acute Lymphoblastic Leukemia.

Authors:  Javier Robles-Valero; L Francisco Lorenzo-Martín; Mauricio Menacho-Márquez; Isabel Fernández-Pisonero; Antonio Abad; Mireia Camós; María L Toribio; Lluis Espinosa; Anna Bigas; Xosé R Bustelo
Journal:  Cancer Cell       Date:  2017-11-13       Impact factor: 31.743
  10 in total
  1 in total

Review 1.  The Vav GEF Family: An Evolutionary and Functional Perspective.

Authors:  Sonia Rodríguez-Fdez; Xosé R Bustelo
Journal:  Cells       Date:  2019-05-16       Impact factor: 6.600
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.